145020.KQ Hugel, Inc.
KOEHealthcareAs of 2026-08-09 03:25
Why 145020.KQ matters now
Hugel, Inc. (145020.KQ) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩273,500.00 with -1.97% on the session and ₩3.42T in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E 20.75, gross margin 77.3%, and operating margin 46.4%.
Valuation
P/E (TTM)
20.75
PEG
—
P/B
3.47
P/S
6.54
EV/EBITDA
11.85
DCF Value
—
FCF Yield
4.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.3%
Operating Margin
46.4%
Net Margin
33.4%
ROE
16.2%
ROA
13.3%
ROIC
14.5%
Listing Info
Market
Korea
Exchange
KOE
Currency
KRW
Sector
Healthcare
Industry
Biotechnology
Country
KR
Hugel, Inc. is a biopharmaceutical firm headquartered in Chuncheon-si, South Korea, with a presence both domestically and internationally. The company specializes in the development and manufacturing of diverse medical solutions. A primary product is its Botulinum Toxin, presented as a clear glass vial containing a white, injectable dry powder. This therapeutic is prescribed for several conditions: treating essential eyelid spasms in adults over 18; ameliorating severe frown lines linked to corrugator and/or procerus muscle activity in adults aged 18 to 65; managing upper limb spasticity following a stroke; and correcting dynamic equinus foot deformity in children with cerebral palsy aged over 2. Furthermore, it aids in improving the lateral canthal lines (crow's feet) caused by orbicularis oculi muscle activity in adults between 19 and 65. This product is marketed under various labels, including Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot. Hugel also provides hyaluronic acid dermal fillers, known as Dermalax and The Chaeum; cosmetic products under the Wellage brand; and medical devices distributed as BlueRose. Hugel, Inc. commenced operations in 2001.